Non-specific immunity of BCG vaccine: A perspective of BCG immunotherapy

Trials in Vaccinology

Volumn 3, Issue , 2014, Pages 143-149

  Iqbal, Najeeha Talat ^a   Hussain, Rabia ^a  

^a AGA KHAN UNIVERSITY   (Pakistan)

Author keywords

BCG vaccine; Cancer; Immunotherapy

Indexed keywords

BCG VACCINE;

ADAPTIVE IMMUNITY; ADJUVANT THERAPY; BCG VACCINATION; BLADDER CANCER; CANCER ADJUVANT THERAPY; CANCER IMMUNOTHERAPY; CANCER PREVENTION; CD4+ T LYMPHOCYTE; CELL ADHESION; HUMAN; IMMUNITY; IMMUNOMODULATION; INNATE IMMUNITY; MELANOMA; MULTICENTER STUDY (TOPIC); NONHUMAN; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; T LYMPHOCYTE ACTIVATION;

EID: 84910058741     PISSN: None     EISSN: 18794378     Source Type: Journal    
DOI: 10.1016/j.trivac.2014.08.002     Document Type: Review

References (88)

1. P.D. Hart, I. Sutherland, BCG and vole bacillus vaccines in the prevention of tuberculosis in adolescence and early adult life, Br. Med. J. 2 (1977) 293-295.
2. J.M. Ponnighaus, P.E. Fine, J.A. Sterne, R.J. Wilson, E. Msosa, P.J. Gruer, et al., Efficacy of BCG vaccine against leprosy and tuberculosis in northern Malawi, Lancet 339 (1992) 636-639.
3. P.E. Fine, Variation in protection by BCG: implications of and for heterologous immunity, Lancet 346 (1995) 1339-1345.
4. N.E. Aronson, M. Santosham, G.W. Comstock, R.S. Howard, L.H. Moulton, E.R. Rhoades, et al., Long-term efficacy of BCG vaccine in American Indians and Alaska Natives: a 60-year follow-up study, JAMA 291 (2004) 2086-2091.
5. R. Brosch, S.V. Gordon, T. Garnier, K. Eiglmeier, W. Frigui, P. Valenti, et al., Genome plasticity of BCG and impact on vaccine efficacy, Proc. Natl Acad. Sci. U. S. A 104 (2007) 5596-5601.
6. P. Fine, P. Small, Exogenous reinfection in tuberculosis, N Eng J Med 341 (1999) 1226-1227.
7. A.D. LaBeaud, I. Malhotra, M.J. King, C.L. King, C.H. King, Do antenatal parasite infections devalue childhood vaccination?, PLoS Negl. Trop. Dis. 3 (2009) e442.
8. P.A. Orege, P.E. Fine, S.B. Lucas, M. Obura, C. Okelo, P. Okuku, Case-control study of BCG vaccination as a risk factor for leprosy and tuberculosis in western Kenya, Int. J. Lepr. Other Mycobact. Dis. 61 (1993) 542-549.
9. S.P. Tripathy, Fifteen year follow-up of the indian BCG prevention trial, Bull Int Union Tuberc Lung Dis 62 (1987) 69-72.
10. G.W. Comstock, S.F. Woolpert, V.T. Livesay, Tuberculosis studies in Muscogee County, Georgia. Twenty-year evaluation of a community trial of BCG vaccination, Public Health Rep. 91 (1976) 276-280.
11. J. Frimodt-Moller, G.S. Acharyulu, K.K. Pillai, Observation concerning the protective effect of BCG vaccination in the rural population of South India: report number 4, Bull Int Union Tuberc 48 (1973) 40-52.
12. L.C. Rodrigues, V.K. Diwan, J.G. Wheeler, Protective effect of BCG against tuberculous meningitis and miliary tuberculosis: a meta-analysis, Int. J. Epidemiol. 22 (1993) 1154-1158.
13. S.S. Cunha, L.C. Rodrigues, V. Pedrosa, I.M. Dourado, M.L. Barreto, S.M. Pereira, Neonatal BCG protection against leprosy: a study in Manaus, Brazilian Amazon, Lepr. Rev. 75 (2004) 357-366.
14. P.E.M. Fine, I.A.M. Carneiro, J.B. Milstien, C.J. Clements, Issues relating to the use of BCG in Immunization Programmes: A Discussion Document, World Health Organization, 1999, pp. 1-45.
15. S.P. Tripathy, The case for B.C.G., Ann. Natl. Acad. Med. Sci. 19 (1983) 11-21.
16. M.S. Setia, C. Steinmaus, C.S. Ho, G.W. Rutherford, The role of BCG in prevention of leprosy: a meta-analysis, Lancet Infect. Dis 6 (2006) 162-170.
17. J. Freund, The mode of action of immunologic adjuvants, Bibl. Tuberc (1956) 130-148.
18. H.C. Yip, A.Y. Karulin, M. Tary-Lehmann, M.D. Hesse, H. Radeke, P.S. Heeger, et al., Adjuvant-guided type-1 and type-2 immunity: infectious/noninfectious dichotomy defines the class of response, J Immunol. 162 (1999) 3942-3949.
19. L. Beck, H.L. Spiegelberg, The polyclonal and antigen-specific IgE and IgG subclass response of mice injected with ovalbumin in alum or complete Freund's adjuvant, Cell Immunol. 123 (1989) 1-8.
20. H. Yagi, M. Matsumoto, S. Suzuki, R. Misaki, R. Suzuki, S. Makino, et al., Possible mechanism of the preventive effect of BCG against diabetes mellitus in NOD mouse. I. Generation of suppressor macrophages in spleen cells of BCG-vaccinated mice, Cell Immunol. 138 (1991) 130-141.
21. C.M. Pearson, Development of arthritis, periarthritis and periostitis in rats given adjuvants, Proc. Soc. Exp. Biol. Med. 91 (1956) 95-101.
22. S.A. Hoption, Cann, J.P.van Netten, and N.C. Van, Dr William Coley and tumour regression: a place in history or in the future, Postgrad. Med. J. 79 (2003) 672-680.
23. S.P. Brown, B.T. Grenfell, An unlikely partnership: parasites, concomitant immunity and host defence, Proc. Biol. Sci. 268 (2001) 2543-2549.
24. M.W. Lightowlers, Fact or hypothesis: Taenia crassiceps as a model for Taenia solium, and the S3Pvac vaccine, Parasite Immunol. 32 (2010) 701-709.
25. F. Chen, Z. Liu, W. Wu, C. Rozo, S. Bowdridge, A. Millman, et al., An essential role for TH2-type responses in limiting acute tissue damage during experimental helminth infection, Nat. Med. 18 (2012) 260-266.
26. H.R. Cabral, The tumoricidal effect of Trypanosoma cruzi: its intracellular cycle and the immune response of the host, Med. Hypotheses 54 (2000) 1-6.
27. B.A. Fox, K.L. Sanders, D.J. Bzik, Non-replicating reverses tumor-associated immunosuppression, Oncoimmunology. 2 (2013) e26296.
28. A. Jemal, M.J. Thun, L.A.G. Ries, Annual report to the nation on the status of cancer, 1975-2005, J Natl Cancer Inst. 100 (2008) 1-23.
29. M.L. Roche, X.-C. Wu, V. Chen, E. Hamilton-Byrd, F.D. Groves, A. Jemal, et al., Cutaneous Melanoma Incidence and Survival Among Black, Asian and Pacific Islander and White Populations in the United States, Clinical Medicine Insights: Dermatology 3 (2010) 24.
30. C. Maire, S. Vercambre-Darras, P. Devos, M. D'Herbomez, S. Dubucquoi, L. Mortier, Metastatic melanoma: spontaneous occurrence of auto antibodies is a good prognosis factor in a prospective cohort, J Eur. Acad. Dermatol. Venereol. 27 (2013) 92-96.
31. E.C. Hsueh, L. Nathanson, L.J. Foshag, R. Essner, J.A. Nizze, S.L. Stern, et al., Active specific immunotherapy with polyvalent melanoma cell vaccine for patients with in-transit melanoma metastases, Cancer 85 (1999) 2160-2169.
32. B. Krone, K.F. Kolmel, J.M. Grange, G. Mastrangelo, B.M. Henz, I.N. Botev, et al., Impact of vaccinations and infectious diseases on the risk of melanoma-evaluation of an EORTC case-control study, Eur. J. Cancer 39 (2003) 2372-2378.
33. K.F. Kolmel, J.M. Grange, B. Krone, G. Mastrangelo, C.R. Rossi, B.M. Henz, et al., Prior immunisation of patients with malignant melanoma with vaccinia or BCG is associated with better survival. An European Organization for Research and Treatment of Cancer cohort study on 542 patients, Eur. J. Cancer 41 (2005) 118-125.
34. S. Hahn, S. Ugurel, K.M. Hanschmann, H. Strobel, C. Tondera, D. Schadendorf, et al., Serological response to human endogenous retrovirus K in melanoma patients correlates with survival probability, AIDS Res. Hum. Retroviruses 24 (2008) 717-723.
35. B. Krone, K.F. Kolmel, B.M. Henz, J.M. Grange, Protection against melanoma by vaccination with Bacille Calmette-Guerin (BCG) and/or vaccinia: an epidemiology-based hypothesis on the nature of a melanoma risk factor and its immunological control, Eur. J. Cancer 41 (2005) 104-117.
36. T.B. Kidner, D.L. Morton, D.J. Lee, M. Hoban, L.J. Foshag, R.R. Turner, et al., Combined intralesional Bacille Calmette-Guerin (BCG) and topical imiquimod for in-transit melanoma, J Immunother. 35 (2012) 716-720.
37. S. Hoshimoto, M.B. Faries, D.L. Morton, T. Shingai, C. Kuo, H.J. Wang, et al., Assessment of prognostic circulating tumor cells in a phase III trial of adjuvant immunotherapy after complete resection of stage IV melanoma, Ann. Surg. 255 (2012) 357-362.
38. D.L. Morton, N. Mozzillo, J.F. Thompson, M.C. Kelley, M. Faries, J. Wagner, et al., MMAIT clinical trial group An international, randomized, phaseIII trial of Bacillus Calmette Guerin (BCG) plus allogeneic melanoma vaccine (MCV) or placebo after complete resection of melanoma metastatic to regional or distant sites, J. Clin. Oncol. 25 (2007) 8508. ASCO Ann Meeting Proc.
39. J.B. Haanen, A. Baars, R. Gomez, P. Weder, M. Smits, T.D.de Gruijl, et al., Melanoma-specific tumor-infiltrating lymphocytes but not circulating melanoma-specific T cells may predict survival in resected advanced-stage melanoma patients, Cancer Immunol. Immunother. 55 (2006) 451-458.
40. S.S. Agarwala, D. Neuberg, Y. Park, J.M. Kirkwood, Mature results of a phase III randomized trial of bacillus Calmette-Guerin (BCG) versus observation and BCG plus dacarbazine versus BCG in the adjuvant therapy of American Joint Committee on Cancer Stage I-III melanoma (E1673): a trial of the Eastern Oncology Group, Cancer 100 (2004) 1692-1698.
41. B.M. Henz, E. Macher, E.B. Brocker, S. Suciu, P.A. Steerenberg, E. Jung, et al., Prognostic value of tuberculin and BCG immunoreactivity in stage I high-risk malignant melanoma (EORTC protocol 18781), Dermatology 193 (1996) 105-109.
42. B.M. Czarnetzki, E. Macher, S. Suciu, D. Thomas, P.A. Steerenberg, et al., Long-term adjuvant immunotherapy in stage I high risk malignant melanoma, comparing two BCG preparations versus non-treatment in a randomised multicentre study (EORTC Protocol 18781), Eur. J. Cancer 29A (1993) 1237-1242.
43. A.B. Alexandroff, A.M. Jackson, M.A. O'Donnell, K. James, BCG immunotherapy of bladder cancer: 20 years on, Lancet 353 (1999) 1689-1694.
44. A. Bohle, P.R. Bock, Intravesical bacille Calmette-Guerin versus mitomycin C in superficial bladder cancer: formal meta-analysis of comparative studies on tumor progression, Urology 63 (2004) 682-686.
45. C. Biot, C.A. Rentsch, J.R. Gsponer, F.D. Birkhauser, H. Jusforgues-Saklani, F. Lemaitre, et al., Preexisting BCG-Specific T Cells Improve Intravesical Immunotherapy for Bladder Cancer, Sci. Transl. Med. 4 (2012) 137ra72.
46. J. Elsasser, M.W. Janssen, F. Becker, H. Suttmann, K. Schmitt, U. Sester, et al., Antigen-specific CD4 T cells are induced after intravesical BCG-instillation therapy in patients with bladder cancer and show similar cytokine profiles as in active tuberculosis, PLoS. One. 8 (2013) e69892.
47. S.K. Schwander, M. Torres, C.C. Carranza, D. Escobedo, M. Tary-Lehmann, P. Anderson, et al., Pulmonary mononuclear cell responses to antigens of Mycobacterium tuberculosis in healthy household contacts of patients with active tuberculosis and healthy controls from the community, J Immunol. 165 (2000) 1479-1485.
48. J.W. Hsu, P.N. Yin, R. Wood, J. Messing, E. Messing, Y.F. Lee, 1 alpha, 25-dihydroxylvitamin D3 promotes Bacillus Calmette-Guerin immunotherapy of bladder cancer, Oncotarget. 4 (2013) 2397-2406.
49. K.A. Heldwein, M.D. Liang, T.K. Andresen, K.E. Thomas, A.M. Marty, N. Cuesta, et al., TLR2 and TLR4 serve distinct roles in the host immune response against Mycobacterium bovis BCG, J. Leukoc. Biol. 74 (2003) 277-286.
50. A.L. Khoo, L.Y. Chai, H.J. Koenen, M. Oosting, A. Steinmeyer, U. Zuegel, et al., Vitamin D(3) down-regulates proinflammatory cytokine response to Mycobacterium tuberculosis through pattern recognition receptors while inducing protective cathelicidin production, Cytokine 55 (2011) 294-300.
51. M.K. Lalor, S. Floyd, P. Gorak-Stolinska, R.E. Weir, R. Blitz, K. Branson, et al., BCG vaccination: a role for vitamin D?, PLoS One. 6 (2011) e16709.
52. A.K. Coussens, R.J. Wilkinson, Y. Hanifa, V. Nikolayevskyy, P.T. Elkington, K. Islam, et al., Vitamin D accelerates resolution of inflammatory responses during tuberculosis treatment, Proc. Natl Acad. Sci. U. S. A 109 (2012) 15449-15454.
53. A.T. Ludwig, J.M. Moore, Y. Luo, X. Chen, N.A. Saltsgaver, M.A. O'Donnell, et al., Tumor necrosis factor-related apoptosis-inducing ligand: a novel mechanism for Bacillus Calmette-Guerin-induced antitumor activity, Cancer Res. 64 (2004) 3386-3390.
54. T.J. Kemp, A.T. Ludwig, J.K. Earel, J.M. Moore, R.L. Vanoosten, B. Moses, et al., Neutrophil stimulation with Mycobacterium bovis bacillus Calmette-Guerin (BCG) results in the release of functional soluble TRAIL/Apo-2L, Blood 106 (2005) 3474-3482.
55. H. Suttmann, M. Jacobsen, K. Reiss, D. Jocham, A. Bohle, S. Brandau, Mechanisms of bacillus Calmette-Guerin mediated natural killer cell activation, J. Urol. 172 (2004) 1490-1495.
56. H. Suttmann, J. Riemensberger, G. Bentien, D. Schmaltz, M. Stockle, D. Jocham, et al., Neutrophil granulocytes are required for effective Bacillus Calmette-Guerin immunotherapy of bladder cancer and orchestrate local immune responses, Cancer Res. 66 (2006) 8250-8257.
57. L. Li, D. Qiao, X. Zhang, Z. Liu, C. Wu, The immune responses of central and effector memory BCG-specific CD4+ T cells in BCG-vaccinated PPD+ donors were modulated by Treg cells, Immunobiology 216 (2011) 477-484.
58. A.P. Soares, C.K. Kwong Chung, T. Choice, E.J. Hughes, G. Jacobs, et al., Longitudinal changes in CD4(+) T-cell memory responses induced by BCG vaccination of newborns, J Infect. Dis. 207 (2013) 1084-1094.
59. O.A. Ovchinnikova, N. Berge, C. Kang, C. Urien, D.F. Ketelhuth, J. Pottier, et al., Mycobacterium bovis BCG killed by extended freeze-drying induces an immunoregulatory profile and protects against atherosclerosis, J Intern. Med. 275 (2014) 49-58.
60. D.L. Faustman, L. Wang, Y. Okubo, D. Burger, L. Ban, G. Man, et al., Proof-of-concept, randomized, controlled clinical trial of Bacillus-Calmette-Guerin for treatment of long-term type 1 diabetes, PLoS One. 7 (2012) e41756.
61. Y.J. Kim, H.J. Kim, M.J. Kang, H.S. Yu, J.H. Seo, H.Y. Kim, et al., Bacillus Calmette-Guerin Suppresses Asthmatic Responses via CD4(+)CD25(+) Regulatory T Cells and Dendritic Cells, Allergy Asthma Immunol. Res. 6 (2014) 201-207.
62. M.M. Coleman, J. Keane, K.H. Mills, Editorial: Tregs and BCG-dangerous liaisons in TB, J Leukoc. Biol. 88 (2010) 1067-1069.
63. S. Burl, U.J. Adetifa, M. Cox, E. Touray, M.O. Ota, A. Marchant, et al., Delaying bacillus Calmette-Guerin vaccination from birth to 4 1/2 months of age reduces postvaccination Th1 and IL-17 responses but leads to comparable mycobacterial responses at 9 months of age, J Immunol. 185 (2010) 2620-2628.
64. K. Takeda, S. Akira, TLR signaling pathways, Semin. Immunol. 16 (2004) 3-9.
65. L.S. Miller, R.L. Modlin, Toll-like receptors in the skin, Semin. Immunopathol. 29 (2007) 15-26.
66. T.S. Kupper, R.C. Fuhlbrigge, Immune surveillance in the skin: mechanisms and clinical consequences, Nat. Rev. Immunol. 4 (2004) 211-222.
67. M.P. Simons, J.M. Moore, T.J. Kemp, T.S. Griffith, Identification of the mycobacterial subcomponents involved in the release of tumor necrosis factor-related apoptosis-inducing ligand from human neutrophils, Infect. Immun. 75 (2007) 1265-1271.
68. R. Medzhitov, P. Preston-Hurlburt, C.A. Janeway Jr., A human homologue of the Drosophila Toll protein signals activation of adaptive immunity, Nature 388 (1997) 394-397.
69. P. Ahmad-Nejad, H. Hacker, M. Rutz, S. Bauer, R.M. Vabulas, H. Wagner, Bacterial CpG-DNA and lipopolysaccharides activate Toll-like receptors at distinct cellular compartments, Eur. J Immunol. 32 (2002) 1958-1968.
70. L. Pompei, S. Jang, B. Zamlynny, S. Ravikumar, A. McBride, S.P. Hickman, P. Salgame, Disparity in IL-12 release in dendritic cells and macrophages in response to Mycobacterium tuberculosis is due to use of distinct TLRs, J. Immunol. 178 (2007) 5192-5199.
71. J. Kleinnijenhuis, L.A. Joosten, F.L.van de Veerdonk, N. Savage, C.R.van, B.J. Kullberg, et al., Transcriptional and inflammasome-mediated pathways for the induction of IL-1beta production by Mycobacterium tuberculosis, Eur, J Immunol. 39 (2009) 1914-1922.
72. P.A. Sieling, D. Chatterjee, S.A. Porcelli, T.I. Prigozy, R.J. Mazzaccaro, T. Soriano, et al., CD1-restricted T cell recognition of microbial lipoglycan antigens, Science 269 (1995) 227-230.
73. L.E. DesJardin, T.M. Kaufman, B. Potts, B. Kutzbach, H. Yi, L.S. Schlesinger, Mycobacterium tuberculosis-infected human macrophages exhibit enhanced cellular adhesion with increased expression of LFA-1 and ICAM-1 and reduced expression and/or function of complement receptors, FcgammaRII and the mannose receptor, Microbiology 148 (2002) 3161-3171.
74. D. Capece, D. Verzella, M. Fischietti, F. Zazzeroni, E. Alesse, Targeting costimulatory molecules to improve antitumor immunity, J Biomed. Biotechnol. 2012 (2012) 926321.
75. S. Prescott, A.M. Jackson, S.J. Hawkyard, A.B. Alexandroff, K. James, Mechanisms of action of intravesical bacille Calmette-Guerin: local immune mechanisms, Clin. Infect. Dis. 31 (Suppl 3) (2000) S91-S93.
76. F. Saint, J.J. Patard, P. Maille, P. Soyeux, A. Hoznek, L. Salomon, et al., Prognostic value of a T helper 1 urinary cytokine response after intravesical bacillus Calmette-Guerin treatment for superficial bladder cancer, J. Urol. 167 (2002) 364-367.
77. A.M. Jackson, A.B. Alexandroff, M. McIntyre, K. Esuvaranathan, K. James, G.D. Chisholm, Induction of ICAM 1 expression on bladder tumours by BCG immunotherapy, J Clin. Pathol. 47 (1994) 309-312.
78. M.G. Netea, T. Azam, G. Ferwerda, S.E. Girardin, M. Walsh, J.S. Park, et al., IL-32 synergizes with nucleotide oligomerization domain (NOD) 1 and NOD2 ligands for IL-1beta and IL-6 production through a caspase 1-dependent mechanism, Proc. Natl. Acad. Sci. U. S. A 102 (2005) 16309-16314.
79. S. Eyerich, K. Eyerich, D. Pennino, T. Carbone, F. Nasorri, S. Pallotta, et al., Th22 cells represent a distinct human T cell subset involved in epidermal immunity and remodeling, J. Clin. Invest 119 (2009) 3573-3585.
80. S. Brandau, H. Suttmann, H.D. Flad, D. Jocham, A. Bohle, Killing of Fas ligand-resistant renal carcioma cells by interleukin-2- and BCG-activated effector cells, Cancer Immunol. Immunother. 49 (2000) 369-376.
81. S. Brandau, J. Riemensberger, M. Jacobsen, D. Kemp, W. Zhao, X. Zhao, et al., NK cells are essential for effective BCG immunotherapy, Int. J. Cancer 92 (2001) 697-702.
82. J. Riemensberger, A. Bohle, S. Brandau, IFN-gamma and IL-12 but not IL-10 are required for local tumour surveillance in a syngeneic model of orthotopic bladder cancer, Clin. Exp. Immunol. 127 (2002) 20-26.
83. S.S. Master, S.K. Rampini, A.S. Davis, C. Keller, S. Ehlers, B. Springer, et al., Mycobacterium tuberculosis prevents inflammasome activation, Cell Host. Microbe 3 (2008) 224-232.
84. P. Johansen, A. Fettelschoss, B. Amstutz, P. Selchow, Y. Waeckerle-Men, P. Keller, V. Deretic, et al., Relief from Zmp1-mediated arrest of phagosome maturation is associated with facilitated presentation and enhanced immunogenicity of mycobacterial antigens, Clin. Vaccine Immunol. 18 (2011) 907-913.
85. M.A. Noor, S.R. Biyabiani, J. Talati, I.A. Burney, Symptomatic Granulomatous Prostatitis following Bacillus Calmette-Guerin Immunotherapy for Bladder Cancer, JPMA, 2002. http://www.jpma.org.pk/full-text.php?article-id=2483.
86. M. Asghar, M.R. Burney, M. Akmal, Effects of intravesical BCG therapy on superficial bladder cancer (recurrence and progression), Pak. Armed Forces Med. J. 54 (2004) 4-6.
87. T.S. Abidi, M. Tahir, Preliminary evidence for curative effect of BCG on chemically induced carcinoma of mammary gland of female albino, Pakistan J Zool 44 (2012) 409-414.
88. M.T. Orr, E.A. Beebe, T.E. Hudson, J.J. Moon, C.B. Fox, S.G. Reed, et al., A dual TLR agonist adjuvant enhances the immunogenicity and protective efficacy of the tuberculosis vaccine antigen ID93, PLoS One. 9 (2014) e83884.